Skip to main content

Arbutus Biopharma Corporation (ABUS)

NASDAQ: ABUS · IEX Real-Time Price · USD
4.01
-0.02 (-0.50%)
After-hours:Oct 22, 2021 7:52 PM EDT
4.03
-0.08 (-1.95%)
At close: Oct 22, 4:00 PM
Market Cap407.55M
Revenue (ttm)8.35M
Net Income (ttm)-84.19M
Shares Out96.87M
EPS (ttm)-0.95
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,042,364
Open4.05
Previous Close4.11
Day's Range3.87 - 4.09
52-Week Range2.43 - 5.87
Beta2.68
AnalystsBuy
Price Target6.00 (+48.9%)
Est. Earnings DateNov 4, 2021

About ABUS

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-83...

IndustryBiotechnology
CEOWilliam Collier
Employees76
Stock ExchangeNASDAQ
Ticker SymbolABUS
Full Company Profile

Financial Performance

In 2020, ABUS's revenue was $6.91 million, an increase of 15.02% compared to the previous year's $6.01 million. Losses were -$63.75 million, -58.53% less than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ABUS stock is "Buy." The 12-month stock price forecast is 6.00, which is an increase of 48.88% from the latest price.

Price Target
$6.00
(48.88% upside)
Analyst Consensus: Buy

News

Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializi...

1 day ago - GlobeNewsWire

Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts

Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?

Other symbols:ADTXADVMENVBEVFM
1 week ago - PennyStocks

5 Penny Stocks To Watch This Week With Potential Biotech Catalysts

Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informatio...

Other symbols:ADVMKLDOMNKDTRVN
2 weeks ago - PennyStocks

Arbutus to Participate in October Investor Conferences

WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercial...

3 weeks ago - GlobeNewsWire

Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

3 weeks ago - Zacks Investment Research

Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations

WARMINSTER, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializ...

1 month ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Arbutus Biopharma (ABUS) Stock?

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.35%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update

New data on AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, highlighted in four abstracts at the EASL International Liver Congress™ ; all AB-729 abstracts selected for best of ILC™

2 months ago - GlobeNewsWire

Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference

WARMINSTER, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializi...

2 months ago - GlobeNewsWire

Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update

WARMINSTER, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializi...

2 months ago - GlobeNewsWire

Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist

Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Informat...

Other symbols:CRBPDBGIJFUNBYNXE
3 months ago - PennyStocks

Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Propriet...

Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic hepatit...

3 months ago - GlobeNewsWire

Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity

The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ:ABUS).

3 months ago - Benzinga

Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care...

Other symbols:VACC
3 months ago - Benzinga

Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729,...

WARMINSTER, Pa. and OXFORD, United Kingdom, July 06, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) and Vaccitech plc (Nasdaq: VACC) today announced that the companies have entere...

3 months ago - GlobeNewsWire

Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination...

MENDHAM, N.J. and WARMINSTER, Pa., June 29, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a cli...

3 months ago - GlobeNewsWire

Best Penny Stocks to Buy Right Now? 7 Small-Caps For Your Morning List

Are these hot penny stocks on your morning watchlist? The post Best Penny Stocks to Buy Right Now?

Other symbols:MRINSBUAMYAHTSENSTNXP
3 months ago - PennyStocks

Arbutus Biopharma Stock Jumps On Encouraging Data From Hepatitis B Candidate

Arbutus Biopharma Corporation (NASDAQ: ABUS) announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver Congress for AB-729 in chronic hepati...

3 months ago - Benzinga

Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL Internationa...

AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks

3 months ago - GlobeNewsWire

Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver ...

Conference Call and Webcast to discuss the new data being presented at EASL  scheduled for 8:00 AM ET, Monday, June 28, 2021

4 months ago - GlobeNewsWire

Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 4.55% and -45.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update

AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV...

5 months ago - GlobeNewsWire

Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update

WARMINSTER, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chroni...

5 months ago - GlobeNewsWire

Arbutus Biopharma Stocks Is Trading Higher On Pan-Coronavirus Research Pact

Arbutus Biopharma Corp (NASDAQ: ABUS), X-Chem Inc, and Proteros biostructures GmbH have entered into discovery, research, and license agreement focused on discovering novel inhibitors targeting the SARS...

6 months ago - Benzinga